Mutant EGFR inhibitor

Cat. No.: HY-13984

CAS No.: 1421373-62-7

Molecular Formula: $C_{27}H_{30}ClN_7O_2$

Molecular Weight: 520.03

Target: EGFR

Pathway: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 50 mg/mL (96.15 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	1.9230 mL	9.6148 mL	19.2297 mL
	5 mM	0.3846 mL	1.9230 mL	3.8459 mL
	10 mM	0.1923 mL	0.9615 mL	1.9230 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Mutant EGFR inhibitor is a potent and selective mutant EGFR inhibitor extracted from patent WO 2013014448 A1; inhibits $EGFR^{L858R}$, $EGFR^{Exon\ 19\ deletion}$ and $EGFR^{T790M}$.

IC_{50} & Target	$EGFR^{L858R}$	$EGFR^{Exon\ 19\ deletion}$	$EGFR^{T790M}$

CUSTOMER VALIDATION

- Cancer Cell. 2017 May 8;31(5):635-652.e6.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. WO 2013014448 A1

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA